Yr in review #ACR22 @RheumNow 🌟GLORIA 2 yr data: 👉Pred 5mg OD vs PBO >65y/o RA ✅⬇️ disease activity (DAS28 -0.38) ✅⬇️ joint damage (sharp/van der heijde -1.7) ❌ 24% ⬆️ a/e “Weigh success in benefit and failure in harm 2 individualise use of low dose pred in RA >65y/o”

Dr. C Langford on #YearinReview: ORAL Surveillance noted NNH=16 in pts w/ASCVD compared to NNH 223 in pts w/o ASCVD. This led to FDA warning on all JAKi; how does not this apply to the new JAKi's? Discussion needed with patients when starting this class of drug #ACR22 @rheumnow https://t.co/XtJVap6yjh

Dr. C Langford #YearinReview: RDBPCT on benefits/harms prednisolone 5 mg/day for 2 years added to SOC in 65yo+ with active RA. Results: improvement in DAS28 (0.37) but AEs occurred in 24% (infection, low bone density)—NNT 9. Study does not apply to younger pts. #ACR22 @rheumnow https://t.co/p2C6IfSje1

GLORIA trial showing low-dose addon pred in older patients with RA showing modest benefit (including reduction in damage) balanced against increased AEs (mostly infection); NNH 9.5! @RheumNow #ACR22 #yearinreview #ACRBest

Year in Review #acr22 Oral Surveillance: With ASCVD number needed to harm 16, only 223 without ASCVD Focus on risk stratification ⁦@RheumNow⁩ https://t.co/tJyha1WKfR

ORAL surveillance the big talking factor over the last year. NNH of 16(!) for CV event (over 5 yrs) in those with history of atherosclerotic CV disease. @RheumNow #ACR22 #yearinreview #ACRBest

Great start to year in review. Beginning with JAKinibs in the much talked about ORAL Surveillance study. Good Review of the mechanisms of action for JAKinibs @RheumNow #ACR22 https://t.co/IF0t4uSefj

Tomorrow at 3 pm at #ACR22! Join my session on Difficult to treat RA - How do define it? - What are the patient and synovial characteristics? - How do we study it? @RheumNow https://t.co/43UEJhYvRp